The FDA Reauthorization Act would reinstate the agency’s user fee program through 2022. The current program, which is set to expire Sept. 30, allows the FDA to collect fees from drug or devicemakers for new product applications. The agency uses these funds — expected to total nearly $9 million by 2022 — to hire more staff and accelerate its product approval processes.
The House unanimously passed the bill last month. It now goes to the president for final approval.
More articles on supply chain:
6 must-reads for supply chain leaders this week
Express Scripts adds 64 drugs to exclusion list
10 most-read supply chain stories in July
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
